BRAF and cutaneous melanoma: First, we examined a clinical study of 39 cutaneous melanoma patients treated with either dabrafenib or vemurafenib, another targeted inhibitor of oncogenic BRAF V600X mutations (Van Allen et al. 2014) (Fig. 4a, Section 2).